Saphenous Vein Graft Disease Clinical Trial
Official title:
Drug Eluting Stents Versus Bare Metal Stents in Saphenous Vein Graft Disease: Insights From a Meta-analysis
A meta-analysis to compare outcomes of drug eluting stents (DES) versus bare metal stent (BMS) in saphenous vein graft (SVG) disease.
To compare outcomes (death, myocardial infarction, target vessel revascularization) of drug eluting stent versus bare metal stent in saphenous vein graft disease. ;
Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02053909 -
Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis
|
Phase 4 | |
Completed |
NCT00263263 -
RRISC Study: Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent.
|
Phase 2 | |
Recruiting |
NCT03175952 -
Virtual Histology Intravascular Ultrasound to Evaluate Prognostic Risks of Saphenous Vein Graft Disease Before Percutaneous Coronary Intervention.
|
N/A | |
Completed |
NCT01528709 -
Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)
|
Phase 3 | |
Completed |
NCT00453518 -
The RETRIEVE Study: Use of the FiberNet® Embolic Protection System in Saphenous Vein Grafts
|
N/A | |
Terminated |
NCT00264706 -
PolyArginine Treated vEiN grafTs (PATENT)
|
Phase 1/Phase 2 | |
Terminated |
NCT01042444 -
Use of the GARDEX™ Embolic Protection Device During Percutaneous Coronary Interventions of Saphenous Vein Graft
|
N/A |